A significant reduction in overall survival (OS) was established in 291 CLL patients from the International Cancer Genome Consortium (ICGC) expressing high UGT2B17 levels (Figure 1A). Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.